For research use only. Not for therapeutic Use.
NS309 (Cat.No:I002418) is a chemical compound known for its ability to activate small-conductance calcium-activated potassium (SK) channels. By modulating these channels, NS309 has shown potential in treating various neurological conditions, such as epilepsy, Parkinson’s disease, and anxiety disorders. Its unique mechanism of action makes NS309 an interesting candidate for further research in neuropharmacology.
| Catalog Number | I002418 |
| CAS Number | 18711-16-5 |
| Synonyms | 6,7-dichloro-3-(hydroxyamino)-2H-indol-2-one |
| Molecular Formula | C8H4Cl2N2O2 |
| Purity | ≥95% |
| Target | Potassium Channel |
| Solubility | DMSO: ≥ 50 mg/mL |
| Storage | Store at -20°C |
| IC50 | Ca2+-activated K+ channel |
| InChIKey | CVOUSAVHMDXCKG-UHFFFAOYSA-N |
| Reference | </br>1:Compromised endothelium-dependent hyperpolarization-mediated dilations can be rescued by NS309 in obese Zucker rats. Tajbakhsh N, Sokoya EM.Microcirculation. 2014 Nov;21(8):747-53. doi: 10.1111/micc.12157. PMID: 25047389 </br>2:NS309 decreases rat detrusor smooth muscle membrane potential and phasic contractions by activating SK3 channels. Parajuli SP, Hristov KL, Soder RP, Kellett WF, Petkov GV.Br J Pharmacol. 2013 Apr;168(7):1611-25. doi: 10.1111/bph.12049. PMID: 23145946 Free PMC Article</br>3:Activation of endothelial and epithelial K(Ca) 2.3 calcium-activated potassium channels by NS309 relaxes human small pulmonary arteries and bronchioles. Kroigaard C, Dalsgaard T, Nielsen G, Laursen BE, Pilegaard H, Köhler R, Simonsen U.Br J Pharmacol. 2012 Sep;167(1):37-47. doi: 10.1111/j.1476-5381.2012.01986.x. PMID: 22506557 Free PMC Article</br>4:IKCa agonist (NS309)-elicited all-or-none dehydration response of human red blood cells is cell-age dependent. Seear RV, Lew VL.Cell Calcium. 2011 Nov;50(5):444-8. doi: 10.1016/j.ceca.2011.07.005. Epub 2011 Sep 21. PMID: 21937109 </br>5:NS309 restores EDHF-type relaxation in mesenteric small arteries from type 2 diabetic ZDF rats. Brøndum E, Kold-Petersen H, Simonsen U, Aalkjaer C.Br J Pharmacol. 2010 Jan;159(1):154-65. doi: 10.1111/j.1476-5381.2009.00525.x. Epub 2009 Dec 10. PMID: 20015296 Free PMC Article</br>6:Urodynamic effects of intravesical administration of the new small/intermediate conductance calcium activated potassium channel activator NS309 in freely moving, conscious rats. Pandita RK, Rønn LC, Jensen BS, Andersson KE.J Urol. 2006 Sep;176(3):1220-4. PMID: 16890729 </br>7:Activation of human IK and SK Ca2+ -activated K+ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). Strøbaek D, Teuber L, Jørgensen TD, Ahring PK, Kjaer K, Hansen RS, Olesen SP, Christophersen P, Skaaning-Jensen B.Biochim Biophys Acta. 2004 Oct 11;1665(1-2):1-5. PMID: 15471565 Free Article |
